Articles tagged with Multiple Sclerosis
Researchers have identified a mechanism to regenerate insulating layers in the brain that protect nerve fibers in multiple sclerosis. The study shows activating stem cells can repair injury in the central nervous system, reversing damage caused by MS.
A new tool has been developed to measure the quality of patient care for people with brain disorders, including Parkinson's disease. The tool evaluates non-motor symptoms, diagnosis and treatment, safety, and more, providing a comprehensive assessment of care.
The American Academy of Neurology has developed a new quality measures tool to help doctors gauge how well they are caring for people with Parkinson's disease, focusing on non-motor symptoms such as depression and falls. The measures aim to improve the quality of care for individuals with neurologic disorders like Parkinson's disease.
Researchers at Purdue University have found evidence that acrolein, an environmental toxin, may play a key role in causing multiple sclerosis. They also discovered that the hypertension drug hydralazine can delay disease onset and reduce symptoms by neutralizing acrolein.
A new compound, ATL313, has shown promise in reversing multiple sclerosis (MS) effects by resetting glial cells to an anti-inflammatory state. The treatment stopped MS-caused paralysis in rats for weeks at a time and could potentially heal lesions, offering a major breakthrough in treating MS symptoms.
Scientists have discovered two new compounds that show promise as treatments for botulism poisoning, building on a multiple sclerosis drug. The compounds did not enter the brain and showed good potential in mice paralyzed by the toxin.
A study of 28 pregnant women with MS found that lower vitamin D levels during pregnancy and breastfeeding were not associated with an increased risk of relapse after childbirth. However, women who breastfed exclusively had lower postpartum vitamin D levels, which may be related to the duration of breastfeeding rather than a causal link.
Recent studies have identified 20 genes associated with multiple sclerosis susceptibility, paving the way for more accurate understanding of the disease. New therapies targeting neuroinflammation and regenerative stem cells hold promise for controlling the disease, mirroring progress made in AIDS treatment.
Researchers found a previously unknown link between two ion channels that can cause symptoms in MS patients. The sodium and leak current channels play a crucial role in signal transmission, and manipulating their balance may lead to new therapeutic opportunities.
Stereotactic radiation is a proven alternative to surgery or anti-epileptic drugs for treating trigeminal neuralgia in MS patients. The study shows that radiosurgery using Gamma Knife is highly effective in reducing pain and improving quality of life for those affected.
Research led by Dr. Fu-Dong Shi at Barrow Neurological Institute revealed that natural killer cells play a critical role in controlling CNS inflammation and immune response. Enriching affected areas with NK cells improved disease symptoms, while blocking them worsened outcomes.
A study found that mindfulness meditation training reduced fatigue and depression in people with mild to moderate multiple sclerosis, improving overall quality of life. The positive effects continued for at least six months.
A new study reveals that immune cells directly interact with and damage neurons in multiple sclerosis, leading to inflammation and neuronal injury. The findings suggest a potential therapeutic target for treating the incurable disease, by modulating calcium levels within neurons.
Researchers explore how genetic variations interact with environmental factors like nicotine, vitamin D, and EBV to accelerate multiple sclerosis progression. The two-year project aims to identify gene-environmental interactions that can inform preventive and therapeutic strategies.
Adding albuterol to a treatment for multiple sclerosis improves functional status and reduces inflammation by decreasing interleukin-12 levels. The study suggests that combining glatiramer acetate with albuterol is well-tolerated and enhances clinical response in patients with relapsing-remitting MS.
A £10 million donation from JK Rowling has led to the establishment of a research clinic focused on patient-based studies for multiple sclerosis. The clinic will explore treatments to slow disease progression, with potential implications for other degenerative neurological conditions.
A study found that multiple sclerosis lesions appeared two to three times higher in spring and summer months compared to other seasons. Warmer temperatures and solar radiation were linked to increased disease activity.
The Society of Interventional Radiology supports high-quality clinical research to determine the safety and effectiveness of interventional M.S. treatments for vulnerable patients. SIR aims to catalyze the development of needed studies, prioritizing individualized assessments and scientific plausibility.
Research reveals vitamin D's impact on multiple sclerosis, rheumatoid arthritis, type 1 diabetes, cancers, and dementia. The study identified 2,776 binding sites for the vitamin D receptor across the genome.
Researchers discovered the function of PTP-PEST, a protein that stimulates T cells' participation in immune responses, potentially leading to new treatments for autoimmune diseases. The study's results suggest that suppressing PTP-PEST could prevent certain autoimmune diseases and weaken overactive immune responses.
Two new studies challenge the CCSVI theory, concluding that blood flow insufficiency does not contribute to MS development. The research refutes the controversial hypothesis, suggesting that venous congestion plays no significant role in MS formation.
A new study found that a gene variant may increase the severity of multiple sclerosis (MS) symptoms, with those having the AA genotype experiencing earlier relapses and increased disease activity. The GG genotype was associated with less disease activity and fewer relapses.
Researchers at UCI have found a new diagnostic tool for multiple sclerosis by detecting increased levels of antibodies that inhibit energy production in neurons. This breakthrough could lead to earlier and more effective treatment for the chronic disease.
A study by Caltech researchers found that specific intestinal bacteria can induce MS-like symptoms in animals, suggesting a link between gut microbes and the disease. The bacteria, from the segmented filamentous bacteria group, were able to replicate and cause inflammation in both the gut and central nervous system.
Researchers at UCLA suggest brain atrophy in hippocampus region may be responsible for depression in people battling multiple sclerosis. A specific sub-region of the hippocampus was found to be smaller in MS patients with depression, and excessive cortisol release from HPA axis was also detected.
A new study published in Neurology found that mentally active lifestyles may reduce the negative effects of brain damage on learning and memory in people with multiple sclerosis. Participants with enriching lifestyles showed better scores on tests of learning and memory despite higher amounts of brain damage.
Research reveals a mechanism for autoimmune disease that depends on killer T cells expressing dual receptors for normal proteins and pathogens. The study found that viruses lacking the specific protein can still trigger the disease, suggesting a complex interplay between viral infections and genetic predisposition.
A UCI study identifies the body's immune system as a key player in navigating transplanted stem cells to injured areas in the central nervous system. Adult neural stem cells were shown to be guided by CXCR-4 receptors and chemokine proteins to specific sites, where they differentiated into oligodendrocytes to repair damaged tissue.
A new study suggests that T helper cells, previously thought to mediate autoimmunity, actually suppress the development of experimental immune encephalomyelitis in mice. The findings indicate that these cells can inhibit the growth of Th17 cells, which are believed to be responsible for causing multiple sclerosis.
Researchers at UCF are exploring new ways to potentially reverse the damage caused by multiple sclerosis and other neurological disorders. The team will study the breakdown of myelin, a substance that coats and protects nerves, with the goal of developing new drugs that can reverse the damage and improve patient outcomes.
A small trial of bone marrow stem cell therapy in patients with MS found the procedure to be well-tolerated and suggested potential benefits. The study's results, published in Clinical Pharmacology and Therapeutics, provide a promising lead for further research into this emerging treatment option.
A breakthrough finding from Tel Aviv University may lead to earlier diagnosis, more effective intervention, and perhaps even a cure for multiple sclerosis. Researchers have uncovered new ways of detecting MS in the blood through their research at Sheba Medical Center, allowing for potential early treatment.
Research suggests that low vitamin D levels are associated with increased disability, brain atrophy, and cognitive impairment in multiple sclerosis patients. Studies found that higher levels of vitamin D3 and its metabolism byproducts were linked to better scores on disability tests and fewer lesions on MRI scans.
A recent MS study analyzed identical twins to identify environmental factors contributing to the disease. The research found that environmental factors play a significant role in multiple sclerosis development, with genes influencing but not determining individual susceptibility.
Patients with multiple sclerosis reported significant improvements in quality of life, physical function, and cognitive abilities after one year of TYSABRI treatment. Fatigue and overall well-being also showed notable reductions.
A new study found that statins can reduce the incidence of new brain lesions in patients with multiple sclerosis by 55.3% compared to a placebo group. This could be meaningful for patients as new lesions are reliable correlates of future clinical attacks.
A new investigational treatment, DMQ, has been shown to effectively control pseudobulbar affect (PBA) in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The study found a significant improvement in test scores after 12 weeks of treatment.
Researchers from Mount Sinai School of Medicine present studies on a potential new drug for multiple sclerosis and surprising trends showing reduced disease severity. The studies found that teriflunomide was safe and effective as part of combination therapy, reducing lesion size and volume in the brain.
A recent study by Boston University School of Public Health researchers found a strong association between vitamin D deficiency and an increased risk of rheumatoid arthritis in women. The study, which analyzed data from the Nurses' Health Study, suggests that higher latitudes may lead to lower levels of vitamin D due to reduced sunligh...
A new study found that smoking increases MS risk in individuals with high levels of Epstein-Barr virus antibody, but not those without it. The research suggests a link between smoking, immune response to the virus, and MS development.
The study supports the utility of Chronix's serum DNA tests to predict clinical status and monitor disease activity in multiple sclerosis. The findings show that the approach can differentiate periods of active disease attacks from stable periods, providing a real-time measure of disease activity.
Researchers found that moderate levels of UV radiation reduced MS symptoms in mice, suggesting a potential link between sunlight and the disease. The study suggests that compounds produced in the skin may play a role in blocking autoimmune damage, paving the way for potential new treatments.
A study found that Epstein-Barr virus infection increases the risk of developing multiple sclerosis by many folds, implicating EBV as a contributing factor. The research followed hundreds of thousands of individuals without EBV infections over several years, providing strong evidence for a causal link.
Researchers from Catholic University of Rome discover that a non-pathogenic bacterium can trigger an autoimmune disease similar to multiple sclerosis in mice. The study suggests that environmental factors may play a role in the development of the disease, and could potentially lead to the development of a vaccine.
Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients. Aerobic fitness has a protective effect on parts of the brain most affected by MS, leading to better performance on tasks that measure processing speed.
A large-scale study found that women with multiple sclerosis (MS) are 47% more likely to develop migraines than those without. The research suggests a link between the two conditions, but further investigation is needed to determine causality.
A Phase 2 trial showed that daclizumab combined with interferon beta reduced MS lesion formation by 72 percent compared to interferon beta alone. The treatment also increased a subset of natural killer cells, associated with a decrease in disease activity.
Researchers found that adding daclizumab to standard treatment for relapsing multiple sclerosis reduced the number of new or enlarged brain lesions. The study also showed an increase in immune cells called CD56bright natural killer cells, which may help regulate the immune system.
Researchers found that 18% of people with an initial stroke had a recurrent stroke within four years, and the risk of recurrence rose steadily after one year. The study highlights the need for better secondary stroke prevention strategies to reduce mortality and morbidity rates.
Researchers found daclizumab, a monoclonal antibody, can reduce new lesion formation in relapsing multiple sclerosis compared to standard interferon beta treatment. The study suggests expanding regulatory CD56bright natural killer cells may play a key role in daclizumab's effects.
A large multiple sclerosis study found that 62.5% of participants exhibited venous insufficiency, a condition linked to blood flow restrictions in the brain. The study suggests a potential association between CCSVI and MS disease progression.
A preliminary study found that drinking milk during pregnancy can reduce the risk of multiple sclerosis (MS) in babies. The study, presented at the American Academy of Neurology's Annual Meeting, revealed that high milk and vitamin D intake during pregnancy lowered the risk of MS by up to 56%.
A new study by neurology researchers at the University at Buffalo found that blacks with multiple sclerosis (MS) have more damage to brain tissue and accumulate lesions faster than whites. This aggressive disease process in blacks is associated with reduced remyelination, a brain's ability to repair the protective myelin sheath.
A study by UCSF researchers found that low vitamin D blood levels are associated with a significantly higher risk of relapse attacks in childhood-onset multiple sclerosis patients. Increasing vitamin D levels can potentially decrease the rate of subsequent relapses.
A new oral drug Cladribine has been shown to significantly reduce multiple sclerosis (MS) relapse and deterioration, with no short-term side effects. The treatment, which only needs to be taken for 8-10 days a year, promises to change the lives of the 100,000 people in the UK affected by MS.
A novel mouse model of demyelinating disorder has been developed, revealing the critical role of gene ZFP191 in CNS myelination. The study found that mice with a mutation in ZFP191 exhibit severe deficiency in CNS myelination, leading to tremors and seizures.
A new guideline from the American Academy of Neurology finds that transcutaneous electric nerve stimulation (TENS) is not effective in treating chronic low-back pain. Research shows conflicting results, but TENS may be beneficial for diabetic nerve pain.
The center will study autoimmune diseases, with a focus on multiple sclerosis and systemic lupus erythematosus, aiming to find new treatments by understanding the immune response mechanisms.
BG-12, an investigational oral therapy, shows promising results in reducing inflammation and neuroprotection in patients with relapsing-remitting multiple sclerosis (RRMS) and rheumatoid arthritis (RA). The compound has activated the Nrf2 pathway, which defends against oxidative-stress induced neuronal death and supports myelin integrity.
A systematic review found that cannabis extracts reduced spasticity and improved mobility in multiple sclerosis patients. The study suggests that combined THC and CBD extracts may provide therapeutic benefits for MS spasticity symptoms.